A Phase One Open-Label Single-Radiolabeled Dose Study to Investigate the Absorption, Metabolism, And Excretion Of [14C] Fruquintinib (HMPL-013) in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2018
At a glance
- Drugs Fruquintinib (Primary)
- Indications Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Hutchison MediPharma
- 24 Mar 2018 Results assessing pharmacokinetics of fruquintinib by using data from two studies including this study presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 27 Oct 2016 Status changed from recruiting to completed.
- 29 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.